Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)
Coleman, Morton, Belada, David, Casasnovas, René-Olivier, Gressin, Rémy, Lee, Hui-Peng, Mehta, Amitkumar, Munoz, Javier, Verhoef, Gregor, Corrado, Claudia, DeMarini, Douglas J., Zhao, Wanying, Li, JJournal:
Leukemia & Lymphoma
DOI:
10.1080/10428194.2020.1832660
Date:
November, 2020
File:
PDF, 1.39 MB
2020